Journal
LEUKEMIA & LYMPHOMA
Volume 49, Issue 8, Pages 1486-1493Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190802140873
Keywords
Hodgkin lymphoma; cardiovascular risk; radiation; chemotherapy; toxicity
Categories
Funding
- Canadian Institute for Health Research [MOP 77515]
Ask authors/readers for more resources
Age- and sex-specific estimates of the rate of cardiac morbidity among Hodgkin lymphoma (HL) patients treated with doxorubicin-based chemotherapy and radiation therapy (RT) are scarce. We evaluated the risk of hospital admission for cardiac disease in 615 HL patients, adjusting for age, sex, treatment, cardiac risk factors and competing causes of death. Compared with the general population, the risk of cardiac morbidity was highest among patients treated with both doxorubicin and mediastinal RT (HR=2.77, p0.0001). Mediastinal RT without chemotherapy also significantly increased the risk (HR=1.82, p=0.038). For females and males treated with doxorubicin plus mediastinal RT at age 40, the estimated 15-year incidence rate of cardiac hospitalisation were 7.3% and 16.5%, respectively, rates 5-15% higher than expected. These results suggest that the risk of clinically important cardiac toxicity following HL treatment that includes both doxorubicin and mediastinal RT may be greater than that reported in prior studies of patients treated with RT alone.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available